Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,957.50    33.00 (1.71%)
Bid:
1,961.00
Ask:
1,961.50
Spread: 0.50 (0.025%)
Market Cap: £78.45b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Director/PDMR Shareholding

21 Feb 2025 07:00

RNS Number : 9160X
GSK PLC
20 February 2025
 

GSK plc (the 'Company')

Vesting of Conditional Share Awards under the Share Value Plan and Sale of Ordinary Shares and American Depositary Shares

This notification sets out the vesting details for Person Discharging Managerial Responsibilities ('PDMRs') of Conditional Share Awards over Ordinary Shares made in 2022 under the GlaxoSmithKline Share Value Plan and the subsequent sale of Ordinary Shares to meet tax liabilities. The awards, which were conditional on continued employment with the GSK group, vested on 17 February 2025.

 

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Tony Wood

b)

Position/status

Chief Scientific Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The vesting of Ordinary Shares awarded in 2022 under the Company's Share Value Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.1829

24,638

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

e)

Date of the transaction

2025-02-17

f)

Place of the transaction

 

N/A

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Tony Wood

b)

Position/status

Chief Scientific Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2022 under the Company's Share Value Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.1829

.

11,580

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

e)

Date of the transaction

2025-02-17

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Victoria Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The vesting of Ordinary Shares awarded in 2022 under the Company's Share Value Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.1829

10,050

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

e)

Date of the transaction

2025-02-17

f)

Place of the transaction

 

N/A

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Victoria Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2022 under the Company's Share Value Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.1829

.

4,724

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

e)

Date of the transaction

2025-02-17

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSEDFLSEISEDE
Date   Source Headline
5th Aug 20257:00 amRNSTransaction in Own Shares
4th Aug 20257:00 amRNSTransaction in Own Shares
1st Aug 20253:00 pmRNSTotal Voting Rights
1st Aug 20257:00 amRNSTransaction in Own Shares
31st Jul 20257:00 amRNSTransaction in Own Shares
30th Jul 20257:05 amRNSTransaction in Own Shares
30th Jul 20257:00 amRNS2nd Quarter Results
29th Jul 20257:00 amRNSTransaction in Own Shares
28th Jul 20257:00 amRNSGSK enters Hengrui Pharma collaboration agreements
28th Jul 20257:00 amRNSTransaction in Own Shares
25th Jul 20257:00 amRNSTransaction in Own Shares
24th Jul 20255:00 pmRNSBlenrep approved in the EU for multiple myeloma
24th Jul 20257:00 amRNSTransaction in Own Shares
23rd Jul 20255:00 pmRNSUS FDA review extended for Blenrep
23rd Jul 20257:00 amRNSTransaction in Own Shares
22nd Jul 20257:00 amRNSTransaction in Own Shares
21st Jul 20257:00 amRNSTransaction in Own Shares
18th Jul 20253:30 pmRNSDirector/PDMR Shareholding
18th Jul 20257:00 amRNSTransaction in Own Shares
18th Jul 20257:00 amRNSBlenrep US ODAC outcome
17th Jul 20257:00 amRNSGSK’s Shingrix Fully Liquid FDA approval
17th Jul 20257:00 amRNSTransaction in Own Shares
16th Jul 20257:00 amRNSTransaction in Own Shares
15th Jul 20253:30 pmRNSDirector/PDMR Shareholding
15th Jul 20257:00 amRNSTransaction in Own Shares
14th Jul 20253:30 pmRNSDirector/PDMR Shareholding
14th Jul 20257:00 amRNSGSK submits Arexvy for adults 18-49 AIR to FDA
14th Jul 20257:00 amRNSTransaction in Own Shares
11th Jul 20257:00 amRNSTransaction in Own Shares
10th Jul 20257:00 amRNSTransaction in Own Shares
9th Jul 20257:00 amRNSTransaction in Own Shares
8th Jul 20257:00 amRNSTransaction in Own Shares
7th Jul 20254:00 pmRNSGSK completes acquisition of efimosfermin for SLD
7th Jul 20257:00 amRNSTransaction in Own Shares
4th Jul 20257:00 amRNSTransaction in Own Shares
3rd Jul 20257:00 amRNSTransaction in Own Shares
2nd Jul 20257:00 amRNSTransaction in Own Shares
1st Jul 20253:00 pmRNSTotal Voting Rights
1st Jul 20257:00 amRNSTransaction in Own Shares
30th Jun 20257:00 amRNSTransaction in Own Shares
27th Jun 20257:00 amRNSTransaction in Own Shares
26th Jun 20257:00 amRNSTransaction in Own Shares
25th Jun 20257:00 amRNSTransaction in Own Shares
24th Jun 20253:30 pmRNSDirector/PDMR Shareholding
24th Jun 20253:00 pmRNSDirector Declaration
24th Jun 20257:00 amRNSTransaction in Own Shares
23rd Jun 20255:50 pmRNSReplacement - Director/PDMR Shareholding
23rd Jun 20253:30 pmRNSDirector/PDMR Shareholding
23rd Jun 20258:30 amRNSReplacement RNS: Linerixibat file accepted by EMA
23rd Jun 20258:18 amRNSGSK Submits Arexvy for adults 18+ with EMA

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.